Stockscreener 앱 받기
1.85
0.54%
-0.01
시간 외 거래:
1.85
전일 마감가:
$1.86
열려 있는:
$1.86
하루 거래량:
735.70K
Relative Volume:
0.78
시가총액:
$200.00M
수익:
$42.51M
순이익/손실:
$-116.49M
주가수익비율:
-1.6518
EPS:
-1.12
순현금흐름:
$-120.82M
1주 성능:
+0.54%
1개월 성능:
-25.70%
6개월 성능:
-80.91%
1년 성능:
-82.77%
1일 변동 폭
$1.72
$1.9838
1주일 범위
$1.72
$2.175
52주 변동 폭
$1.72
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
TNGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
1.85 | 200.00M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday - Defense World
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity - MSN
Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough - Simply Wall St
Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint - Yahoo Finance UK
Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks
Tango Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Tango Therapeutics, Inc. SEC 10-K Report - TradingView
Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times
Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Can Tango's Cancer Breakthroughs in Pancreatic and Lung Cancer Outweigh Its Growing Losses? - StockTitan
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter
Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences - The Manila Times
Can Tango's Synthetic Lethality Approach Transform Cancer Treatment? Key Conferences to Watch - StockTitan
Tango Therapeutics executive sells shares worth $43,865 - MSN
Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Declines By 22.5% - MarketBeat
Analysts Offer Predictions for TNGX Q3 Earnings - MarketBeat
Q1 Earnings Forecast for TNGX Issued By Leerink Partnrs - MarketBeat
Q3 Earnings Forecast for TNGX Issued By Leerink Partnrs - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) CEO Barbara Weber Sells 9,778 Shares - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Daniella Beckman Sells 4,284 Shares - MarketBeat
Adam Crystal Sells 7,432 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock - MarketBeat
Tango Therapeutics Inc (NASDAQ: TNGX): Can A Stock Be -1.94% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel
Tango Therapeutics CEO Barbara Weber sells $57,710 in stock - MSN
One Tango Therapeutics Insider Raised Stake By 400% In Previous Year - Yahoo Finance
What is Leerink Partnrs’ Estimate for TNGX Q1 Earnings? - Defense World
Tango Therapeutics CFO Beckman sells $25,281 in stock - MSN
Tango Therapeutics CFO Beckman sells $25,281 in stock By Investing.com - Investing.com South Africa
Tango Therapeutics CEO Barbara Weber sells $57,710 in stock By Investing.com - Investing.com Australia
Tango Therapeutics executive sells shares worth $43,865 By Investing.com - Investing.com Australia
Tango Therapeutics general counsel Barry Douglas sells $16,369 in stock - MSN
Is Tango Therapeutics Inc (TNGX) worth investing in despite its overvalued state? - US Post News
TNGX’s 2023 Market Dance: Up 8.41% – Time to Invest? - The InvestChronicle
Exclusive BAC Article: Tango Therapeutics; 2nd Half Of 2024 MTAP-Deletion Tumor Data TNG-908/TNG-462, TNG-260 Phase 1/2 Trial Advancement And Catalysts (NASDAQ:TNGX) - Seeking Alpha
TNGX (Tango Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
Tango Therapeutics Inc’s Market Journey: Closing Strong at 3.04, Up 4.47 - The Dwinnex
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $13.14 Average Price Target from Analysts - MarketBeat
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference - The Manila Times
Precision Cancer Medicine Pioneer Tango Therapeutics Takes Center Stage at Elite Biotech Conference - StockTitan
Tango Therapeutics: Chance For A Short Squeeze - Seeking Alpha
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.14%
2.83%
자본화:
|
볼륨(24시간):